Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received one dose of Shingrix 5 years ago when it first came out. Due to a reaction, it was decided to hold off on the 2nd dose. Two months ago, I received the Shingrix vaccine again with no reaction; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received one dose of Shingrix 5 years ago when it first came out). In DEC-2025, the patient received the 2nd dose of Shingrix. In DEC-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received one dose of Shingrix 5 years ago when it first came out. Due to a reaction, it was decided to hold off on the 2nd dose. Two months ago, I received the Shingrix vaccine again with no reaction). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 11-FEB-2026 The patient inquired whether he/she still needed to receive the second dose now. The batch number was not provided and a request for this information had been made.